pipeline

ICT-121

ICT-121 specifically targets CD133, a cancer stem cell marker that is overexpressed in a wide variety of solid tumors, including ovarian, pancreatic, and breast cancers.

The phase 1 open-label trial of ICT-121 in patients with recurrent glioblastoma has completed enrollment, reaching the target of 20 patients. The trial is being conducted at six sites in the US and preliminary results are expected about mid-year 2017.

ICT-121

Copyright 2017 by Immunocellular Therapeutics, Ltd.
All Rights Reserved